Posterity Health Raises $6 million to Fund Expansion and Technology Acceleration:
The Center of Excellence for Male Care
DENVER -- (BUSINESS WIRE)--Posterity Health, the center of excellence for male reproductive health, today announced the closing of its latest round of financing led by FCA Venture Partners and supported by Distributed Ventures and WVV. Posterity Health empowers males to take control of their reproductive health.
The incremental funding will be used to accelerate the development of the Posterity Health Male Management Platform (MMP), launch new services and expand the executive team.
The Posterity Health Male Management Platform (MMP)
The Posterity Health MMP combines innovative technology, expert care teams and AI driven clinical protocols to drive personalized end-to-end male care. The MMP is designed to facilitate efficient access, enabling the company to scale rapidly providing access to more males. It enables us to contact 99% of patients on the same day we receive their referral and see 75% of patients within 2 weeks. Trained reproductive urologists and their specialized care teams drive a hybrid care delivery model, allowing for telehealth appointments and in person care. This unique model ensures continuity of care and includes MMP data analytics and AI modules allowing the company to unlock the power of the clinical data collected. This platform will enable real time research providing new insights into male fertility care and treatment.
New Services
Hormone Management is a $3.2 billion dollar market in the United States. This funding event enables Posterity Health to expand beyond fertility to provide a full suite of reproductive services including Low-T services. Expert Hormone Management cost effectively improves the overall health status of all males.
Executive Team Expansion
The company is excited to welcome Matt Alley as Chief Operating Officer. Matt has a powerful track record scaling complex service businesses. Matt most recently served as Sr. Director of Fulfillment Strategy at Hello Fresh. Prior to Hello Fresh, he held senior leadership roles at TruePill, Alto Pharmacy and Amazon.
“I’m excited to contribute to Posterity Health’s vision of making significant advancements in male reproductive health. We are committed to innovation and excellence in every aspect of our patient care.”
In another move to fuel growth, Matt Lenz was promoted to Chief Growth Officer. Matt has over a decade of experience in the health care industry, expanding markets and growing market share. Prior to joining Posterity Health, Matt served as Vice President of Sales at Teladoc. He also led teams at Livongo (acquired by Teladoc), Netsmart Technologies and HealthMEDX. Matt and his team support obgyn and fertility center partners and manage strategic relationships with the leading fertility benefit managers. The team recently launched a new initiative into the self-insured employer market, further expanding access to care.
“Developing and leading the team at Posterity Health has been a career highlight. The growth we’ve seen over the past couple of years demonstrates the need for quality, easy to access care male care,” says Matt.
“These executive leaders share a common vision to provide every male with the knowledge, resources and support to optimize their reproductive health,” Pam Pure, Co-founder and CEO. “We are excited about this important next chapter of growth and innovation.”
About Posterity Health:
Posterity Health is the only virtual-first center of excellence for male reproductive health. We provide a hybrid care delivery model, allowing for telehealth appointments, ongoing treatment plans and in person care powered by Posterity Health’s Male Management Platform. Through innovative technologies, personalized care and expert guidance, Posterity Health empowers males to take control of their reproductive health.
Learn more at www.posterityhealth.com.
About FCA Venture Partners
FCA Venture Partners is a venture capital firm investing in early-stage healthcare technology and technology-enabled healthcare services companies that improve patient care, reduce costs, or increase efficiency. FCA manages over $225 million and invests across the Series Seed to Series B stages. FCA brings portfolio companies valuable healthcare insights, connections, and board-level experience to accelerate growth and build disruptive and sustainable businesses. Based in Nashville, the epicenter of healthcare innovation, and Charlotte, the FCA team has a decades-long track record including more than 60 investments in the rapidly changing healthcare industry.